Leif Bostad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Leif Bostad has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alf Inge Larsen
Department of Cardiology, Stavanger University Hospital, Stavanger, Norway
1 shared publication - Anders Molven
Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway
1 shared publication - Dagny Ann Sandnes
Institute of Surgery, University of Bergen, 5021 Bergen, Norway
1 shared publication - Dennis Winston Trygve Nilsen
Department of Cardiology, Stavanger University Hospital, 4068 Stavanger, Norway
1 shared publication Hans J. Aarstad
Department of Otolaryngology and Head and Neck Surgery Haukeland University Hospital Bergen Norway
1 shared publication- Henry Wabinga
Department of Pathology, College of Health Sciences, Makerere University, Kampala, Uganda
1 shared publication
Latest Publications
Diagnostic yield of biopsies of cervical lymph nodes using a large (14‐gauge) core biopsy needle
The purpose of this study was to assess retrospectively complications and diagnostic yield of core needle biopsy (CNB) of cervical lymph nodes using 14‐gauge as sole needle bore. During a 10‐year period ultrasound (US)‐guided CNB, using a 14‐gauge Tru‐Cut needle (non‐advancing), was performed in 140 consecutive cases (135 patients, aged 8–88 years) when a detailed histological diagnosis was required to guide therapy. CNB findings were consistent with the final diagnosis in 129 of the 140 cases, comprising 36 benign lesions, 40 metastases, and 53 lymphomas (40 NHL and 13 HL) of which subclassification (WHO criteria) was partial in 5NHL, and complete in 35 (87.5%) NHL and 13 HL (100%), including all 7 lymphomatous nodes with short‐axis diameter ≤1.0 cm. Two lymphomas were falsely interpreted as reactive hyperplasia. Nine samples (6.4%) were inadequate for histopathological analysis. One patient experienced pain in an arm lasting 3–4 days. No other immediate or delayed complications were diagnosed. A 14‐gauge may be used safely as the sole needle bore in US‐guided CNB of cervical lymph nodes, rendering samples sufficient for full subtyping in lymphoma, even in the smallest nodes.
Diagnostic yield of biopsies of cervical lymph nodes using a large (14‐gauge) core biopsy needle
The purpose of this study was to assess retrospectively complications and diagnostic yield of core needle biopsy (CNB) of cervical lymph nodes using 14‐gauge as sole needle bore. During a 10‐year period ultrasound (US)‐guided CNB, using a 14‐gauge Tru‐Cut needle (non‐advancing), was performed in 140 consecutive cases (135 patients, aged 8–88 years) when a detailed histological diagnosis was required to guide therapy. CNB findings were consistent with the final diagnosis in 129 of the 140 cases, comprising 36 benign lesions, 40 metastases, and 53 lymphomas (40 NHL and 13 HL) of which subclassification (WHO criteria) was partial in 5NHL, and complete in 35 (87.5%) NHL and 13 HL (100%), including all 7 lymphomatous nodes with short‐axis diameter ≤1.0 cm. Two lymphomas were falsely interpreted as reactive hyperplasia. Nine samples (6.4%) were inadequate for histopathological analysis. One patient experienced pain in an arm lasting 3–4 days. No other immediate or delayed complications were diagnosed. A 14‐gauge may be used safely as the sole needle bore in US‐guided CNB of cervical lymph nodes, rendering samples sufficient for full subtyping in lymphoma, even in the smallest nodes.
- Open Access
- 1 January 2010
- Published by Springer Nature in Thrombosis Journal
- Vol. 8 (1) , 1
The activity of pregnancy-associated plasma protein A (PAPP-A) as expressed by immunohistochemistry in atherothrombotic plaques obtained by aspiration thrombectomy in patients presenting with a ST-segment elevation myocardial infarction: a brief communication
The expression of pregnancy-associated plasma protein A (PAPP-A) was identified by immunohistochemistry (IHC) in culprit atherothrombotic plaque specimens harvested from patients admitted with ST-segment elevation myocardial infarction (STEMI).
- 1 January 2010
- Published by Springer Nature in Thrombosis Journal
- Vol. 8 (1) , 1
Open AccessThe activity of pregnancy-associated plasma protein A (PAPP-A) as expressed by immunohistochemistry in atherothrombotic plaques obtained by aspiration thrombectomy in patients presenting with a ST-segment elevation myocardial infarction: a brief communication
The expression of pregnancy-associated plasma protein A (PAPP-A) was identified by immunohistochemistry (IHC) in culprit atherothrombotic plaque specimens harvested from patients admitted with ST-segment elevation myocardial infarction (STEMI).
- Open Access
- 19 August 2009
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 9 (1) , 6
pRb2/p130 protein expression and RBL2 mutation analysis in Burkitt lymphoma from Uganda
Background: The members of the retinoblastoma protein family, pRb, p107 and pRb2 (p130), are central players in controlling the cell cycle. Whereas disturbed function of pRb is commonly seen in human cancers, it is still an open question whether pRb2 is involved in tumorigenic processes. However, altered subcellular localization of pRb2 and mutations in the pRb2-encoding gene RBL2 have been described for some tumours, including Burkitt lymphomas (BL). Methods: We retrieved 51 biopsy specimens of endemic BL cases from Uganda. The expression of pRb2 was determined by immunohistochemistry. Exons 19-22 of the RBL2 gene, the region known to contain a nuclear localization signal, were screened for mutations by PCR amplification and direct DNA sequencing. Results: Nearly all of our cases (84.0%) were positive for pRb2 protein expression although this protein is a marker for growth arrest and Burkitt lymphoma is characterized by a high proliferation rate. Of the positive cases, 73.8% were scored as expressing the protein at a high level. Subcellular pRb2 localization was predominantly nuclear and no cases with expression restricted to the cytoplasm were observed. We did not detect any RBL2 mutations in the part of the gene that encodes the C-terminal end of the protein. Conclusion: The majority of endemic BL cases from Uganda express pRb2, but somatic RBL2 mutations affecting the protein's nuclear localization signal appear to be rare.
- 19 August 2009
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 9 (1) , 6
Open AccesspRb2/p130 protein expression and RBL2 mutation analysis in Burkitt lymphoma from Uganda
Background: The members of the retinoblastoma protein family, pRb, p107 and pRb2 (p130), are central players in controlling the cell cycle. Whereas disturbed function of pRb is commonly seen in human cancers, it is still an open question whether pRb2 is involved in tumorigenic processes. However, altered subcellular localization of pRb2 and mutations in the pRb2-encoding gene RBL2 have been described for some tumours, including Burkitt lymphomas (BL). Methods: We retrieved 51 biopsy specimens of endemic BL cases from Uganda. The expression of pRb2 was determined by immunohistochemistry. Exons 19-22 of the RBL2 gene, the region known to contain a nuclear localization signal, were screened for mutations by PCR amplification and direct DNA sequencing. Results: Nearly all of our cases (84.0%) were positive for pRb2 protein expression although this protein is a marker for growth arrest and Burkitt lymphoma is characterized by a high proliferation rate. Of the positive cases, 73.8% were scored as expressing the protein at a high level. Subcellular pRb2 localization was predominantly nuclear and no cases with expression restricted to the cytoplasm were observed. We did not detect any RBL2 mutations in the part of the gene that encodes the C-terminal end of the protein. Conclusion: The majority of endemic BL cases from Uganda express pRb2, but somatic RBL2 mutations affecting the protein's nuclear localization signal appear to be rare.